Stereotactic body radiotherapy (SBRT) is an emerging radiotherapy technique that precisely delivers high doses of radiation to tumours. It has been investigated as definitive treatment for an increasing variety of primary tumours including lung, liver, prostate, and now renal cell carcinoma (RCC). The principal aims of this study are to prospectively assess quality of life (QoL) and oncologic outcomes in non-surgical patients who receive SBRT for the treatment of RCC.
There is an evolving body of literature that shows high rates of tumour control and minimal associated toxicities with SBRT to treat RCC. However, the majority of published evidence is retrospective in nature, and there is a scarcity of data on the impact on quality of life and cost-effectiveness of kidney SBRT. The principal aims of this multicentre study are to prospectively assess QoL and oncologic outcomes in non-surgical patients who receive SBRT for the treatment of primary renal cell carcinoma. The study population will include 30 consecutive patients treated with kidney SBRT on a conventional linear accelerator (35-40 Gy in 5 fractions) at the Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto (OCC) and the Juravinski Cancer Center, Hamilton Health Sciences Centre, McMaster University (JCC).
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
30
35-40 Gy delivered in 5 fractions
Juravinski Cancer Centre
Hamilton, Ontario, Canada
Odette Cancer Centre, Sunnybrook Health Science Centre
Toronto, Ontario, Canada
Patient Quality of Life
To evaluate quality of life scores
Time frame: Up to 5 years after treatment
Cost-Effectiveness
To assess health utility scores and correlate with QoL
Time frame: Up to 5 years after completion of treatment
Oncologic Outcomes
To evaluate local control
Time frame: Up to 5 years after completion of treatment
Oncologic Outcomes
To evaluate progression-free survival
Time frame: Up to 5 years after completion of treatment
Oncologic Outcomes
To evaluate overall survival
Time frame: Up to 5 years after completion of treatment
Treatment-Related Toxicity
To report number of participants with treatment-related toxicities as assessed by CTCAE v4.0
Time frame: Up to 5 years after completion of treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.